{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023194","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.246782+00:00","generated_at":"2026-06-22T04:20:38.427438+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ALX Oncology Q3 net loss widens to $35.3M; secures $100M loan facility, extends cash runway to mid-2025","bullets":["GAAP net loss $35.3M ($0.87/diluted share) vs $24.6M ($0.61) in Q3 2021; non-GAAP loss $29.1M vs $20.4M.","Cash, equivalents, investments $293.1M; $100M term loan facility ($10M drawn) extends runway to mid-2025.","R&D expenses $29.4M (up 62% YoY) on increased clinical trial costs; G&A $7.3M (up 14%).","Initial Phase 1 ASPEN-05 AML data showed no MTD, full CD47 occupancy, anti-leukemic activity; ASH poster Dec 12, 2022.","New clinical trial arms: I-SPY-P1 for HER2 breast cancer (evorpacept + ENHERTU); Phase 2 CRC trial first patient dosed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023194","json":"https://secwatch.observer/filing/0000950170-22-023194.json","markdown":"https://secwatch.observer/filing/0000950170-22-023194.md","text":"https://secwatch.observer/filing/0000950170-22-023194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017022023194/0000950170-22-023194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017022023194/alxo-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:20:38.427438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2e53ef56bc962f03ebafeade5baaeba26a6cf6e","claim":"ALX ONCOLOGY HOLDINGS INC reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, ALX Oncology Holdings Inc. (the \"Company\"), issued a press release announcing its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017022023194/0000950170-22-023194-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}